Why Eli Lilly Stock Is Sinking Today

Shares of Eli Lilly and Company (NYSE: LLY) were sinking 8.7% as of 10:42 a.m. EDT on Monday. The big drop came after the drugmaker presented data on Saturday from a phase 2 study of donanemab in treating Alzheimer's disease. Investors were disappointed by Lilly's results.

There was good news from Lilly's study. The company reported that donanemab met the primary endpoint of slowing decline on the integrated Alzheimer's Disease Rating Scale (iADRS) compared to placebo. The iADRS is a composite scale that measures cognition and daily function with Alzheimer's disease patients. Lilly said patients receiving donanemab had a 32% reduction in iADRS score compared to patients on placebo.

Image source: Getty Images.

Continue reading

Source Fool.com